cas 17412-23-6|| where to buy 6-Chloro-2,8-dimethylimidazo[1,2-b]pyridazine

Product Name:6-Chloro-2,8-dimethylimidazo[1,2-b]pyridazine

IUPAC Name:6-chloro-2,8-dimethylimidazo[1,2-b]pyridazine

Packing Unit	Available Stock	Price($)
CM330120-50mg	in stock	ŪŪ
CM330120-100mg	in stock	ǆȤȅ
CM330120-250mg	in stock	ǆƐƚ
CM330120-1g	in stock	ƚȤƴ
CM330120-5g	in stock	Ȗƴƴ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 17412-23-6 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:17412-23-6; Molecular Formula:C8H8ClN3; Melting Point:-; Smiles Code:CC1=CC(Cl)=NN2C1=NC(C)=C2; Density:

: Catalog Number:CM330120; Molecular Weight:181.62; Boiling Point:; MDL No:MFCD27946129; Storage:

: Imidazopyridazines; Potent IRAK-4 inhibitors have been reported by several groups including some structurally related benzimidazoles as well as alternative fused heterocycles such as the imidazopyridine and imidazopyridazine. Such compounds are reported to have IRAK-1 and IRAK-4 activity with varying degrees of selectivity.

: Risdiplam; As the first approved small molecule splicing modifier drug, Risdiplam (Evrysdi) is granted approval by the European Commission to expand the EU marketing authorization. This extension now includes infants with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies from birth to below two months. Type 1 spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease and a leading genetic factor of infant mortality, that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam modifies SMN2 pre-messenger RNA splicing and increases levels of functional SMN protein in both the central nervous system and peripheral organs.